Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Cisplatin
  • Neoplasms, Glandular and Epithelial
  • Receptor, Epidermal Growth Factor
  • Recombinant Fusion Proteins

abstract

  • C225 has dose-dependent pharmacokinetics, and doses that achieve saturation of systemic clearance are well tolerated. C225 given in combination with cisplatin has biologic activity at pharmacologically relevant doses.

publication date

  • February 2000

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 10673534

Additional Document Info

start page

  • 904

end page

  • 14

volume

  • 18

number

  • 4